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Abstract
Background: Resistance and tolerance to Plasmodium falciparum can determine the progression of malaria disease.
However, quantitative evidence of tolerance is still limited. We investigated variations in the adverse impact of P.
falciparum infections among African pregnant women under different intensities of malaria transmission.
Methods: P. falciparum at delivery was assessed by microscopy, quantitative PCR (qPCR) and placental histology in
946 HIV-uninfected and 768 HIV-infected pregnant women from Benin, Gabon, Kenya and Mozambique. Resistance
was defined by the proportion of submicroscopic infections and the levels of anti-parasite antibodies quantified by
Luminex, and tolerance by the relationship of pregnancy outcomes with parasite densities at delivery.
Results: P. falciparum prevalence by qPCR in peripheral and/or placental blood of HIV-uninfected Mozambican,
Gabonese and Beninese women at delivery was 6% (21/340), 11% (28/257) and 41% (143/349), respectively. The
proportion of peripheral submicroscopic infections was higher in Benin (83%) than in Mozambique (60%) and
Gabon (55%; P = 0.033). Past or chronic placental P. falciparum infection was associated with an increased risk of
preterm birth in Mozambican newborns (OR = 7.05, 95% CI 1.79 to 27.82). Microscopic infections were associated
with reductions in haemoglobin levels at delivery among Mozambican women (–1.17 g/dL, 95% CI –2.09 to –0.24)
as well as with larger drops in haemoglobin levels from recruitment to delivery in Mozambican (–1.66 g/dL, 95% CI
–2.68 to –0.64) and Gabonese (–0.91 g/dL, 95% CI –1.79 to –0.02) women. Doubling qPCR-peripheral parasite
densities in Mozambican women were associated with decreases in haemoglobin levels at delivery (–0.16 g/dL,
95% CI –0.29 to –0.02) and increases in the drop of haemoglobin levels (–0.29 g/dL, 95% CI –0.44 to –0.14).
Beninese women had higher anti-parasite IgGs than Mozambican women (P < 0.001). No difference was found in
the proportion of submicroscopic infections nor in the adverse impact of P. falciparum infections in HIV-infected
women from Kenya (P. falciparum prevalence by qPCR: 9%, 32/351) and Mozambique (4%, 15/417).
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Conclusions: The lowest levels of resistance and tolerance in pregnant women from areas of low malaria transmission
were accompanied by the largest adverse impact of P. falciparum infections. Exposure-dependent mechanisms
developed by pregnant women to resist the infection and minimise pathology can reduce malaria-related adverse
outcomes. Distinguishing both types of defences is important to understand how reductions in transmission can affect
malaria disease.
Trial registration: ClinicalTrials.gov NCT00811421. Registered 18 December 2008.
Keywords: Malaria, Pregnancy, Immunity, Resistance, Tolerance
Background
As the rest of the population, pregnant women living in
areas of different malaria endemicity experience varying
degrees of exposure to infection, which affects the acqui-
sition of antimalarial immunity and determines the
course of disease [1, 2]. Protective immunity to Plasmo-
dium falciparum in pregnancy has been suggested to
rely mostly on antibodies against VAR2CSA that block
adhesion of infected erythrocytes to placental chondroitin
sulphate A, and thereby prevent parasite sequestration in
the placenta [3]. Such immune resistance to P. falciparum,
which is acquired after exposure to placental-type para-
sites, reduces parasite densities below the detection limit
of microscopy (i.e. submicroscopic infections) [4–6] and
can eventually clear placental infections.
Infected hosts may also tolerate the presence of P. fal-
ciparum by minimising parasite-induced damage with-
out necessarily limiting the infection [7–9]. This type of
host defence, not to be confused with immunological
tolerance [7, 10], has been suggested by the frequent ob-
servation in malaria endemic areas of individuals,
including pregnant women, who harbour levels of para-
sitaemia in their blood that would commonly be associ-
ated with fever in malaria-naïve individuals [11, 12].
Moreover, the higher risk of life-threatening disease in
younger age groups [13] supports the notion that the
ability to modulate host inflammation (anti-disease or
clinical immunity) [14, 15] develops faster than the cap-
acity to restrict parasite growth (anti-parasite immunity).
However, other studies do not support the hypothesis
that a special clinical immunity exists independently of
parasitological immunity [16], but rather suggest that
immunity resulting in decreased parasite densities re-
duces the severity of symptoms.
Resolving the role of resistance and tolerance could
aid the development of host-directed therapies to reduce
malaria-induced immunopathology and mitigate malaria
disease [9]. However, quantitative analyses of tolerance
to human malaria have been mainly limited to the as-
sessment of peripheral P. falciparum parasitemia needed
to trigger the onset of fever (i.e. pyrogenic threshold)
[14, 15]. Alternative clinical outcomes and analytical
frameworks are needed for pregnant women in whom
parasitaemia is poorly associated with fever [17]. Here,
we aimed to assess the variations in the clinical impact
of P. falciparum infections and in host defences devel-
oped by pregnant women under different malaria trans-
mission intensities. To achieve this, we compared the
carriage of submicroscopic infections and antibodies
against P. falciparum antigens as indicators of the level
of parasitological immunity [1]. We assessed the correl-
ation between health outcomes (haemoglobin levels and
birthweight) and parasite densities at delivery for sum-
marising tolerance [8], with a flat slope indicative of tol-
erance to infection. As immune resistance is strongly
influenced by the number of previous pregnancies in
areas of stable transmission [18] and pregnancy outcomes
can be affected by the preventive measures used during
pregnancy, analyses were adjusted for parity of the preg-
nant women and the antimalarials received as intermittent
preventive treatment during pregnancy (IPTp).
Methods
Study populations
This study was conducted between 2010 and 2012 in four
sub-Saharan countries (Additional file 1: Figure S1),
namely Benin (Allada, Sékou and Attogon), Gabon (Lam-
baréné and Fougamou), Kenya (Siaya), and Mozambique
(Manhiça and Maragra). Pregnant women were enrolled in
the context of the Malaria in Pregnancy Preventive Alter-
native Drugs clinical trial (ClinicalTrials.gov NCT0081121;
Table 1) [19, 20]. At enrolment, pregnant women received
long-lasting insecticide-treated bed-nets. Following na-
tional guidelines in place, HIV status was assessed after
voluntary HIV counselling and testing with an HIV rapid
test and positive results were confirmed with a second
rapid test [19, 20]. Haemoglobin and the syphilis rapid
plasma reagin (RPR) test were assessed as part of routine
antenatal care on finger-prick-collected capillary blood.
Among HIV-infected women, 5 mL of venous blood were
taken for CD4 + T cell count by flow cytometry after
staining of whole blood with CD3, CD8 and CD4
fluorochrome-labelled antibodies. Flow cytometry acquisi-
tion was performed using FACSCalibur (BD Biosciences)
and TruCOUNT tubes (Becton Dickinson). Additionally,
viral load determination was performed using the COBAS
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Table 1 Characteristics of participants by study area
HIV-uninfecteda HIV-infectedb
All Benin Gabon Mozambique All Kenya Mozambique
n = 946 n = 349 n = 257 n = 340 n = 768 n = 351 n = 417
Age (years), mean (SD)
24.3 (6.3) 25.4 (5.2) 24.4 (6.7) 23.1 (6.8) 26.7 (5.7) 26.9 (5.4) 26.5 (5.9)
Parity, n (%)
Primigravidae 265 (28) 69 (20) 66 (26) 130 (38) 81 (11) 30 (9) 51 (12)
Multigravidae 681 (72) 280 (80) 191 (74) 210 (62) 687 (89) 321 (91) 366 (88)
Gestational age at baseline (weeks), mean (SD)
21.0 (4.9) 22.0 (4.1) 19.5 (5.4) 21.3 (5.2) 20.3 (5.5) 19.9 (5.9) 20.6 (5.2)
MUAC at baseline (cm), mean (SD)
25.9 (3.0) 25.3 (2.3) 25.7 (3.6) 26.8 (3.0) 26.8 (2.7) 27.0 (2.7) 26.7 (2.7)
RPR at baseline, n (%)
Positive 9 (1) 2 (1) 1 (0) 6 (2) 39 (5) 12 (3) 27 (7)
Negative 928 (99) 347 (99) 247 (100) 334 (98) 726 (95) 338 (97) 388 (93)
Literate, n (%)
No 371 (39) 280 (80) 34 (13) 57 (17) 142 (18) 16 (5) 126 (30)
Yes 575 (61) 69 (20) 223 (87) 283 (83) 626 (82) 335 (95) 291 (70)
HIV viral load (copies/mL) at baseline, n (%)c
< 399 181 (24) 125 (36) 56 (13)
400/999 183 (24) 76 (22) 107 (26)
1000/9999 243 (32) 97 (28 146 (35)
10,000/max 123 (16) 49 (14) 74 (18)
UNK 38 (5) 4 (1) 34 (8)
CD4 (cells/μL) at baseline, n (%)d
< 350 279 (36) 137 (39) 142 (34)
350/max 460 (60) 212 (60) 248 (59)
UNK 29 (4) 2 (1) 27 (6)
Maternal haemoglobin at baseline (g/dL), mean (SD)
10.4 (1.5) 10.3 (1.2) 10.3 (1.4) 10.7 (1.8) 10.1 (1.7) 10.2 (1.9) 10.0 (1.6)
IPTp, n (%)
Antimalarial 1e 629 (66) 230 (66) 172 (67) 227 (67) 390 (51) 174 (50) 216 (52)
Antimalarial 2e 317 (34) 119 (34) 85 (33) 113 (33) 378 (49) 177 (50) 201 (48))
Gestational age at delivery (weeks),f mean (SD)
39.6 (1.7) 39.2 (1.2) 41.1 (1.8) 38.9 (1.2) 38.8 (1.2) ND 38.8 (1.2)
Preterm birth,g n (%)
No 867 (95) 328 (95) 238 (95) 301 (95) 374 (96) ND 374 (96)
Yes 44 (5) 16 (5) 13 (5) 15 (5) 17 (4) ND 17 (4)
aThe IPTp trial evaluated the efficacy and safety of two doses of Intermittent Preventive Treatment in pregnancy (IPTp) with mefloquine compared to IPTp
with sulphadoxine-pyrimethamine
bEvaluated three doses of IPTp with MQ compared to placebo in HIV-infected women on cotrimoxazole prophylaxis
c38 missing values
d29 missing values
eAntimalarial: 1 = Mefloquine and 2 = Sulphadoxine-Pyrimethamine for HIV-uninfected; 1 = Placebo and 2 =Mefloquine for HIV-infected
fGestational age was estimated by newborn physical examination using the Ballard score
gPreterm birth if gestational age was < 37 weeks
IPTp intermittent preventive treatment, MUAC mid-upper arm circumference, RPR rapid plasma reagin, UNK unknown
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AMPLICOR or AmpliPrep (Roche Diagnostics) devices.
Haemoglobin was determined in capillary blood samples
using mobile devices (HemoCue and Hemocontrol) [19,
20]. Gestational age at enrolment was determined from
symphysis fundal height measurement using a standard
tape measure (centimetres) and McDonald’s rule to trans-
form the symphysis fundal height in centimetres into ges-
tational weeks [19, 20]. Following physical examination,
recruited women with gestational age ≥ 13 weeks received
their first dose of IPTp (either sulfadoxine-pyrimethamine
(SP) or mefloquine (MQ) for HIV-uninfected women and
either placebo or MQ for HIV-infected women) under
supervision. Women allocated to the SP group received
standard IPTp (three tablets of the fixed combination ther-
apy containing 500 mg of sulfadoxine and 25 mg of pyri-
methamine), whereas participants allocated to the MQ
groups received 15 mg/kg of the drug. The second IPTp-
SP/MQ administration for HIV-uninfected women, and
the second and third administrations of IPTp-MQ/
placebo for HIV-infected women, were given at least
1 month apart. All HIV-infected women also received
study co-trimoxazole tablets on a monthly basis for
daily prophylaxis.
At delivery, maternal haemoglobin was determined
and newborns were weighed using weekly calibrated
scales (either digital or three beam balances) and their
gestational age at birth (except for Kenyan newborns)
was evaluated using the Ballard’s score [21]. Newborn
weights not captured at birth but within the first week
of life were estimated using a linear regression model
[22]. Peripheral and placental blood smears, as well as
50 μL of maternal peripheral and placental blood spotted
onto filter paper, were collected for parasitological as-
sessments. Tissue samples were also collected from the
maternal side of the placenta and placed into 10% neu-
tral buffered formalin. Biopsies were processed, stained
and examined following standard procedures [23]. From
the first antenatal visit, all study women were indicated
to receive ferrous sulphate-folic acid supplements for
prevention of anaemia in pregnancy. If a woman was di-
agnosed with anaemia, she was treated with oral ferrous
sulphate 200 mg/8 hours for 3 months or blood transfu-
sion for severe cases. Clinical malaria episodes were
treated with oral quinine (first trimester) or artemether-
lumefantrine (subsequent trimesters) for uncomplicated
malaria; parenteral quinine was used for treatment of se-
vere malaria [19, 20].
Parasitological determinations
Thick and thin blood films, as well as placental biopsies,
were read for Plasmodium species detection according
to standard, quality-controlled procedures [19, 20, 24].
The quality of the reading across sites was controlled
through a quality control program during the study. Past
placental infection was defined by the presence of P. fal-
ciparum pigment (i.e. hemozoin) without parasite detec-
tion on placental histologic examination, and chronic
placental infection was defined by the presence of P. fal-
ciparum pigment in combination with the detection of
parasites [1]. A 30% random selection of paired periph-
eral and placental blood onto filter papers from HIV-
negative women [20] and all the paired filter papers
from HIV-infected women [19] were tested for the pres-
ence and density of P. falciparum in duplicate by means
of a real-time quantitative polymerase chain-reaction
(qPCR) targeting 18S rDNA [1, 25]. Parasitemia was
quantified by extrapolation of cycle thresholds from a
standard curve of P. falciparum ring-infected erythro-
cytes. Samples without amplification (no cycle thresh-
olds detected) were considered negative, and a density of
2 parasites/μL was assigned if amplification was ob-
served out of the lower range of the standard curve (5
parasites/μL). A negative control with no template DNA
was run in all reactions. P. falciparum infections were
considered submicroscopic if parasites were detected by
qPCR but not by microscopy [1]. A quality check pro-
gram was established to ensure comparable performance
of qPCR techniques in different laboratories [25].
Measurement of antimalarial IgGs and P. falciparum
Histidine-Rich Protein 2 (PfHRP2)
A random selection of 50% of peripheral plasma samples
collected at delivery from HIV-uninfected women in the
extremes of the malaria transmission spectrum (n = 170
from Benin and n = 170 from Mozambique) was tested for
IgG levels against P. falciparum recombinant VAR2CSA
domain (DBL3X from 3D7 strain), and the merozoite sur-
face protein-1 (MSP-119; 19-kD fragment, 3D7 strain)
using a multiplex suspension array panel (xMAPTM tech-
nology) and the Luminex® 100/200™ System (Luminex
Corp., Austin, TX, USA) [1]. Briefly, magnetic carboxyl-
ated microspheres (MagPlexTM-C, Luminex) were coupled
with recombinant protein. After blocking with bovine
serum albumin in phosphate-buffered saline, micro-
spheres were sequentially incubated with 100 μL of
plasma (dilutions 1:500, 1:20,000 and 1:800,000 in dupli-
cate for each sample), 100 μL of biotinylated anti-human
IgG (diluted 1:2500) and 100 μL of streptavidin-
conjugated R-phycoerythrin (diluted 1:1000). The plate
was immediately read using Bio-Plex Manager version 4.0,
and at least 50 microspheres per analyte were acquired
per sample. Crude mean fluorescent intensity was
exported with background fluorescence from blank wells
already subtracted. PfHRP2 [26] was quantified in plasmas
available from women with peripheral qPCR-detected P.
falciparum infection at delivery (n = 42 in Benin and n =
13 in Mozambique) using a commercial HRP2 antigen-
capture ELISA (Malaria Ag CELISA kit; Cellabs) [27].
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Statistical analysis
Pregnant women were included in the analysis if they had
all information on IPTp type of treatment, HIV infection,
age, parity, newborn weight, maternal haemoglobin levels,
as well as qPCR results in peripheral and placental blood
at time of delivery. Women were classified as primigravid
(first pregnancy) and multigravid (at least one previous
pregnancy). Age was categorised as < 25 and ≥ 25 years on
the basis of median maternal age in the study population.
Preterm birth was defined as a gestational age < 37 weeks.
Participant’s baseline characteristics, parasitological out-
comes, antimalarial IgG levels and PfHRP2 levels were
compared between study areas by univariate analysis and
logistic or lineal regression models. Changes in maternal
haemoglobin levels and birthweight with increases in
qPCR-peripheral parasite density were assessed by linear
regression. The impact of P. falciparum infections on
haemoglobin levels, birthweight and preterm birth was
assessed in logistic regression models. Continuous out-
come variables (qPCR-parasite densities, antimalarial IgGs
and HRP2 levels) exhibiting a skewed distribution were
log transformed. Regression models were estimated
through a backward stepwise approach with a significance
level for removal from the model of 0.1 and a significance
level for addition of 0.05, adjusted by type of IPTp drug
and baseline covariates at recruitment (season, age, gravid-
ity, gestational age, anaemia, literacy, RPR result and mid-
upper arm circumference (MUAC)), as well as CD4 + T
cell count in the case of HIV-infected women [19, 20].
The modification of the associations by study area was
assessed by including interaction terms into the regression
models and combining the coefficients plus the inter-
action and the standard error by the delta method. P
values of less than 0.05 were considered to indicate
statistical significance. Stata version 13 was used for
data analysis and GraphPad version 5.01 for graphical
depiction of data.
Results
P. falciparum burden in the study populations
A total of 1714 pregnant women, 946 (55%) HIV-
uninfected and 768 (45%) HIV-infected, were included
in this study (Table 1 and Additional file 1: Figure S1).
The 3428 peripheral and placental filter papers from
these 946 HIV-uninfected and 768 HIV-infected women
were tested for the presence and density of P. falciparum
by qPCR [25, 28]. Covariates at recruitment were similar
in the study subgroup and the rest of the women partici-
pating in the randomised trial [19, 20] (Additional file 1:
Table S1). Prevalence of qPCR-detected P. falciparum at
delivery, either in peripheral blood at delivery or placen-
tal blood (maternal qPCR infection in Table 2), was 41%
(143/349) in Benin, 11% (28/257) in Gabon and 6% (21/
340) in Mozambique (P < 0.001) among HIV-uninfected
women, and 9% (32/351) in Kenya and 4% (15/417) in
Mozambique (P < 0.001) among HIV-infected women
(Fig. 1a and Table 2). Similar trends were observed for
maternal microscopic infections (Fig. 1b and Table 2).
The relationship between microscopy positivity and
qPCR parasitaemia in the different study sites is pre-
sented in Additional file 1 (Table S2). The proportion
of samples that were negative by microscopy but for
which qPCR indicated a parasitaemia above 200 para-
sites/μL was not different between sites (Additional
file 1: Table S3).
Effects of P. falciparum infection on health outcomes
Microscopic P. falciparum infection detected at delivery
in peripheral blood and/or the placenta of Mozambican
women was associated with a reduction of 1.17 g/dL (95%
CI –2.09 to –0.24, P = 0.014) in their haemoglobin levels,
but this reduction was not observed among Beninese nor
Gabonese women (P = 0.581 and P = 0.154, respectively;
Fig. 2a). Microscopic infections were also associated with
larger drops in haemoglobin levels from recruitment to
delivery in Mozambican (–1.66 g/dL, 95% CI –2.68 to –
0.64, P = 0.001) and Gabonese (–0.91 g/dL, 95% CI –1.79
to –0.02, P = 0.045) women, but not among Beninese
women (P = 0.213; Fig. 2c). No impact of microscopic P.
falciparum infection in the mother was observed on the
birthweight, irrespective of study area (Fig. 2e). However,
past or chronic placental P. falciparum infection, defined
by the presence of P. falciparum pigment (i.e. hemozoin)
on placental histologic examination, was associated with a
reduction of 247.2 g (95% CI –479.1 to –15.2, P = 0.037)
in the birthweight of Mozambican babies, which was not
observed in Benin (P = 0.569) and Gabon (P = 0.486).
Given the strong association between birthweight and ges-
tational age at delivery (Additional file 1: Table S4), the
regression model assessing the relationship between birth-
weight and infection was adjusted by preterm birth, show-
ing a loss of statistical significance (P = 0.192). However,
past or chronic placental P. falciparum infection were as-
sociated with an increased risk of preterm birth in Mo-
zambican newborns (OR = 7.05, 95% CI 1.79 to 27.82, P =
0.005), but not among Beninese (P = 0.785) and Gabonese
newborns (P = 0.639). Microscopic P. falciparum infection
was not associated with reductions in haemoglobin levels
of HIV-infected women from Kenya and Mozambique
nor with reductions of birthweight (Fig. 2b, d, f ). Finally,
no adverse clinical impact was observed for P. falciparum
submicroscopic infections, defined by the detection of P.
falciparum by qPCR but not by microscopy, irrespective
of the HIV-infectious status of the pregnant women (Add-
itional file 1: Figure S2). Adjusting variables that remained
in the final regression models and interactions assessed
with parity, age and IPTp treatment are detailed in Table
S5 and S6 of Additional file 1.
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Submicroscopic P. falciparum infections, antimalarial
immunity and HRP2 levels
The proportion of peripheral submicroscopic infections
among HIV-uninfected women was the highest in Benin
(83%; 82/106), followed by Mozambique (60%, 9/15) and
Gabon (55%, 12/22, Padjusted = 0.033; Fig. 3a). Similar
trends, although not statistically significant, were observed
for placental submicroscopic infections (82% (78/95), 58%
(10/17) and 71% (15/21), respectively, Padjusted = 0.674;
Fig. 3b). Among pregnant women with a qPCR-detected
infection either in peripheral or placental blood, the pro-
portion of submicroscopic infections in any of the two
compartments was the highest in Benin (94%, 124/132),
followed by Gabon (82%, 18/22) and Mozambique (74%,
14/19, Padjusted = 0.028). PfHRP2 concentrations, indicative
of overall parasite biomass [26], were higher in pregnant
women with a peripheral qPCR-detected infection from
Mozambique (n = 13) than from Benin (n = 42, P = 0.048;
Fig. 3c). HRP2 levels decreased with parity of pregnant
women in Benin (0.13, 95% CI 0.02 to 0.79, P = 0.028) but
not in Mozambique (1.09, 95% CI 0.09 to 12.21, P =
0.945). In contrast, age was not associated with differences
in HRP2 levels among Beninese (P = 0.052) and Mozambi-
can women (P = 0.123). Levels of IgGs against DBL3X
from VAR2CSA and MSP1 were higher in women from
Benin than in women from Mozambique (P < 0.007;
Fig. 3d). IgG responses against MSP1 increased with parity
of Beninese pregnant women (2.39, 95% CI 1.49 to
Table 2 Parasitological outcomes in peripheral blood and placenta by study area
HIV-uninfected HIV-infected
Benin Gabon Mozambique P Kenya Mozambique P
Periphery at delivery
Smear, n (%)
Negative 320 (92) 245 (96) 333 (98) 0.002a 332 (95) 408 (98) 0.025a
Positive 27 (8) 11 (4) 7 (2) 17 (5) 8 (2)
qPCR, n (%)
Negative 242 (69) 235 (91) 325 (96) <0.001a 326 (93) 405 (97) 0.007a
Positive 107 (31) 22 (9) 15 (4) 25 (7) 12 (3)
qPCR parasites/μL, GM (SD) 280.5 (882.9) 684.2 (1703.2) 514.4 (1630.6) 0.484 141.4 (329.1) 3350.9 (9887.2) 0.003
Placenta
Smear, n (%)
Negative 322 (93) 244 (96) 332 (98) 0.018a 335 (95) 406 (98) 0.032a
Positive 23 (7) 9 (4) 8 (2) 16 (5) 7 (2)
Histology, n (%)
Acute 8 (2) 5 (2) 1 (0) <0.001 6 (2) 4 (1) <0.001
Chronic 23 (7) 2 (1) 2 (1) 5 (1) 1 (0)
Past 37 (11) 28 (11) 13 (4) 64 (18) 14 (3)
No infected 277 (80) 218 (86) 322 (95) 276 (79) 387 (95)
qPCR, n (%)
Negative 253 (72) 235 (91) 323 (95) <0.001a 324 (92) 407 (98) 0.001a
Positive 96 (28) 22 (9) 17 (5) 27 (8) 10 (2)
qPCR parasites/μL, GM (SD) 668.5 (2473.1) 1284.9 (5100.0) 1876.2 (5910.5) 0.609 379.5 (1255.4) 5851.3 (19950.4) 0.033
Maternal microcopy infection,b n (%)
Negative 294 (87) 239 (95) 329 (97) <0.001a 325 (93) 396 (98) 0.002a
Positive 45 (13) 12 (5) 9 (3) 24 (7) 9 (2)
Maternal qPCR infection,b n (%)
Negative 206 (59) 229 (89) 319 (94) <0.001a 319 (91) 402 (96) <0.001a
Positive 143 (41) 28 (11) 21 (6) 32 (9) 15 (4)
aThe P value is significant according to multivariate analysis adjusted for type of IPTp drug, season, age, gravidity, gestational age, anaemia, literacy, RPR result
and MUAC at recruitment, as well as CD4 + T cell count in the case of HIV-positive women (Wald test) (ND for placental histology)
bMaternal infections were considered microscopic if P. falciparum parasites were observed in peripheral blood at delivery or in placental blood from the maternal
side either by microscopy or histology and qPCR infections if peripheral blood at delivery or placental blood samples were positive by qPCR
GM geometric mean, SD standard deviation
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3.83, P < 0.001) but not among Mozambican pregnant
women (P = 0.401). IgG responses against DBL3x in-
creased with parity of Beninese and Mozambican pregnant
women although the magnitude of the increase was higher
among Beninese (4.77, 95% CI 3.08 to 7.38, P < 0.001) than
Mozambican women (1.86, 95% CI 1.23 to 2.79, P = 0.003;
Fig. 3e). Age was not associated with differences in IG re-
sponses irrespectively of antigen and study area (P = 0.223
for MSP1 and P = 0.171 for DBL3X in Benin and P = 0.959
for MSP1 and P = 0.380 for DBL3X in Mozambique). No
differences in covariates at recruitment were observed be-
tween the women with plasma available for serological
tests and the rest of the women. The proportion of sub-
microscopic infections did not differ among HIV-infected
women from Kenya and Mozambique (Fig. 3a, b).
P. falciparum densities and pregnancy outcomes
Doubling qPCR parasite densities in peripheral blood of
HIV-uninfected Mozambican women was associated
with a reduction of 0.16 g/dL (95% CI –0.29 to –0.02, P
= 0.023) in their haemoglobin levels. In contrast, haemo-
globin levels remained unaffected by increasing parasite
densities in Beninese (P = 0.287) and Gabonese women
(P = 0.381; Fig. 4a and Additional file 1: Figure S3). Simi-
larly, doubling qPCR parasite densities in peripheral
blood of HIV-uninfected Mozambican women was asso-
ciated with a larger drop in the haemoglobin levels from
recruitment to delivery (–0.29 g/dL, 95% CI –0.44 to –
0.14, P < 0.001), while no relationship was found in Be-
ninese (P = 0.076) and Gabonese women (P = 0.176;
Fig. 4c and Additional file 1: Figure S3). No association
was found between qPCR parasite densities and birth-
weight irrespectively of the country of women, nor with
pregnancy outcomes in HIV-infected women (Fig. 4).
Discussion
Although the importance of tolerance in the context of
P. falciparum infection was suggested early on [29], the
Fig. 2 Impact of microscopic malaria infections at delivery on
pregnancy outcomes. Maternal microscopic infections were considered
present if P. falciparum parasites were observed in peripheral blood at
delivery and/or in the placenta either by microscopy or histology. The
dot and T bar represents the mean difference and 95% confidence
interval in haemoglobin levels at delivery (a, b), the difference of
haemoglobin levels from recruitment to delivery (c, d), or birth
weight (e, f) between malaria infected and uninfected women in
the multivariate regression analysis adjusted for type of IPTp drug,
season, age, gravidity, gestational age, anaemia, literacy, RPR result
and MUAC at recruitment, plus CD4 + T cell count at recruitment in
the case of HIV-infected women (b, d, f). Modification of the associations
by study area (B Benin, G Gabon, K Kenya, M Mozambique) was
determined through the inclusion of an interaction term in the
regression models, and combination of the coefficients plus the
interaction and the standard error was estimated by the delta method
Fig. 1 Prevalence of P. falciparum maternal infection according to study area. Prevalence of P. falciparum at delivery in peripheral and/or placental
blood as detected by qPCR (a) and microscopy (b). P value according to the multivariate analysis adjusted for type of IPTp drug, season, age, gravidity,
gestational age, anaemia, literacy, RPR result and MUAC at recruitment, as well as CD4 + T cell count in the case of HIV-infected women. T bars
represent standard errors. B Benin, G Gabon, M Mozambique, K Kenya
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link between such a host defence strategy and malaria
disease has been obscured by the difficulties of quantify-
ing the tolerance phenotype. We sought to reduce the
complexity of tolerance to a single metric based on the
relationship between parasite densities and health out-
comes (haemoglobin levels and birthweight) [8], with a
flat slope indicative of tolerance to infection. To assess
for variations in the levels of resistance to P. falciparum
among women from the different endemic areas, we
used the proportion of submicroscopic infections at de-
livery and IgG levels against parasite antigens as an indi-
cator of the ability of pregnant women to restrict
parasite growth [1]. Here, we have demonstrated that
the lowest levels of immune resistance and tolerance ob-
served among HIV-uninfected Mozambican women,
compared to women from Benin, were accompanied by
the largest adverse impacts of P. falciparum infections.
Thus, the reduced severity of infections observed in
pregnant women from high endemic regions [1] may not
be mediated entirely by an adaptive immune response to
the parasite, but also by a tolerance to P. falciparum, as
quantified by the slope of the relationship between
parasite densities and haemoglobin levels [8]. Taken to-
gether, these results provide evidence that pregnant
women develop exposure-dependent mechanisms to
minimise malaria pathology which, in concert with im-
mune resistance, can reduce the adverse impact of P. fal-
ciparum infections.
Variation in resistance to P. falciparum among HIV-
uninfected women from three sub-Saharan African
countries was suggested by different proportions of sub-
microscopic infections. Prevalence of qPCR-detected P.
falciparum infections at delivery ranged from 41% in
Benin to 11% in Gabon and 6% in Mozambique. Preg-
nant women from Benin had the highest proportion of
submicroscopic infections at delivery, suggesting an in-
creased capacity to maintain infections at densities bellow
the detection limit of microscopy. These observations are
in contrast with trends reported showing a significantly
higher percentage of infections detected by microscopy in
the general population residing in areas of high compared
to those in low transmission areas [30]. These discrepan-
cies may suggest a special dynamic and progression of P.
falciparum infection during pregnancy compared to
Fig. 3 Proportion of P. falciparum submicroscopic infections, PfHRP2 concentrations and antibody responses against P. falciparum antigens
according to study area. Proportion of infections that are submicroscopic in peripheral (a) and placental (b) blood. P value according to the
multivariate analysis adjusted for type of IPTp drug, season, age, gravidity, gestational age, anaemia, literacy, RPR result and MUAC at recruitment,
as well as CD4 + T cell count in the case of HIV-infected women. T bars represent standard errors. B Benin, G Gabon, M Mozambique, K Kenya.
c PfHRP2 concentrations, indicative of overall parasite biomass, among women with a peripheral qPCR-detected infection in Mozambique
(M; n = 13) and Benin (B; n = 42). d Levels of IgG antibodies against MSP1 and DBL3X in Beninese (n = 170) and Mozambican (n = 170) women.
e Levels of IgG antibodies against MSP1 and DBL3X by parity (primigravidae (PG) versus multigravidae (MG)), with the proportional increase (Δ) of
the antibody levels plus 95% confidence interval in multigravidae versus primigravidae women. P values obtained from regression analysis adjusted for
type of IPTp drug, season, gravidity, gestational age, anaemia, literacy, RPR result and MUAC at recruitment, as well as CD4 + T cell count in the case of
HIV-infected women. MFI mean fluorescence intensity
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infections in non-pregnant hosts. In line with this,
PfHPR2 levels in plasma, indicative of total parasite bio-
mass [26], were lower among Beninese than Mozambican
women, whereas levels of anti-parasite antibodies, as well
as the increase with parity of IgGs against DBL3X from
VAR2CSA, were higher in women from Benin than from
Mozambique. Overall, these data supports the notion that
the acquisition of antimalarial immunity after exposure to
P. falciparum parasites can increase the capacity to resist
P. falciparum growth during subsequent infections in
pregnancy.
Variations in tolerance to P. falciparum were also ob-
served in pregnant women living under contrasting
levels of malaria transmission, as indicated by differences
in the relationship between haemoglobin levels and in-
creasing parasite burden. In this study, haemoglobin
levels at delivery decreased as parasite densities in-
creased in HIV-uninfected women from the lowest
transmission setting in Mozambique. By contrast, the
haemoglobin level in HIV-uninfected Beninese and
Gabonese women were not affected by parasite density,
indicating a better tolerance to the infection [7]. Parasite
factors such as the level of resistance to SP, as well as
the protective effect of IPTp with SP against adverse
birth outcomes that are related to curable sexually trans-
mitted and reproductive tract infections [31, 32], may
affect the clinical impact of infections among pregnant
women who received antimalarials as IPTp. However, no
relationship was observed between the level of molecular
markers of SP resistance in the parasite population
based on the frequencies of dihydropteroate synthase
(Pfdhps) K540E mutation [33, 34] previously reported
(>90% Pfdhps-K540E in Kenya [33] but < 50% in
Mozambique [35], Gabon [36] and Benin [37]) and the
outcomes of the study. Moreover, the efficacy of IPTp
with SP to clear peripheral parasites and prevent new in-
fections during pregnancy has been suggested to be
compromised only in areas with > 90% prevalence of
Pfdhps K540E mutation [33]. Taken together, these re-
sults suggest that immunoregulatory responses that re-
duce pathogenic inflammation and potentially the risk of
anaemia [38] may be developed by pregnant women ex-
posed to P. falciparum, as has been suggested for chil-
dren [39–41].
In absence of HIV infection, the adverse clinical im-
pact of P. falciparum infections was the highest in
pregnant women from the low transmission site in
Mozambique, who had the lowest levels of immune re-
sistance and tolerance to P. falciparum. This adverse im-
pact was observed for microscopic P. falciparum
infections, which were associated with reductions in ma-
ternal haemoglobin levels at delivery as well as with in-
creased drops in haemoglobin levels from recruitment to
delivery, but not with birthweight. Moreover, placental
past/chronic infections among Mozambican women
were associated with an increased risk of preterm births,
in accordance with previous studies showing a larger im-
pact of infections during pregnancy compared to infec-
tions detected only at delivery [42–44]. Such an adverse
effect of placental past/chronic infections on the birth-
weight of newborns was not observed among Beninese
or Gabonese women. P. falciparum microscopic infec-
tion in Gabonese women was also associated with an in-
creased drop in haemoglobin levels from recruitment to
delivery, although of a lower magnitude than the drop
observed in Mozambican women. These data suggest
that the malaria-related adverse impact in the health of
pregnant women is higher in Gabon than in Benin, but
lower than in Mozambique. Such an intermediate sever-
ity of the infections in Gabonese women might be
explained by the development of tolerance to P. falcip-
arum (as suggested by the lack of an association between
haemoglobin levels with increasing parasite densities) ra-
ther than by immune resistance to the infection (as
Fig. 4 Relationship of qPCR-detected parasite densities in peripheral
blood with pregnancy outcomes. The dot and T bar represent the
effect and 95% confidence interval on haemoglobin levels at delivery
(a, b), the difference of haemoglobin levels from recruitment to delivery
(c, d), or birth weight (e, f) due to a two-fold increase in the parasitemia
levels in its natural scale. Modification of the associations by study area
(B Benin, G Gabon, K Kenya, M Mozambique) was determined through
the inclusion of an interaction term in the regression models, and
combination of the coefficients plus the interaction and the standard
error was estimated by the delta method. Analyses were adjusted for
type of IPTp drug, season, age, gravidity, gestational age, anaemia,
literacy, RPR result and MUAC at recruitment, as well as CD4 + T cell
count in the case of HIV-infected women (b, d, f)
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indicated by the similar carriage of submicroscopic in-
fections in Gabonese and Mozambican women). Overall,
this evidence suggests that resistance and tolerance to
malaria can be acquired after exposure to P. falciparum
parasites in areas of high transmission, and can reduce
the detrimental consequences of P. falciparum infec-
tions. Importantly, HIV-infected pregnant women from
Kenya and Mozambique did not show any evidence of
varying levels of resistance or tolerance, suggesting that
the ability to limit the adverse impact of P. falciparum
infection may be reduced when the immune system is
suppressed by the viral infection [45].
This study has some limitations. First, P. falciparum
infection at delivery in women who received IPTp most
likely reflect a recently acquired infection. Thus, this
study may under-estimate the adverse impact of P. fal-
ciparum infections during pregnancy, as compared to re-
cent reports showing that submicroscopic P. falciparum
infection at inclusion (16.5 weeks) increases the risk of
low birth weight for primigravid and premature delivery
for multigravid pregnant Beninese women [6]. Second,
other factors apart from anti-parasite immunity may
contribute to the carriage of submicroscopic infections,
such as the stage of the infection, the chronicity of infec-
tions, which is most common among primigravid
women without immunity to placental parasites [46],
and the existence of suppressive levels of antimalarial
drugs. Third, site-specific differences in the extent of
healthcare provided and economic development, as well
as other factors than can affect pregnancy outcomes (i.e.
haemoglobinopathies), might contribute to variations in
the clinical impact of infections among pregnant women
from different countries. However, the impact of these
differences was minimised by the fact that this study was
performed in the context of a clinical trial following
standard procedures [19, 20] and that the analysis was
adjusted by potential confounders. Fourth, the immuno-
logical analyses were conducted only in a subset of
plasma samples available from the women included in
the study, which were similar in covariates with the rest
of the women. Fifth, analyses were performed by group,
rather than at the individual level, assuming uniform ex-
posure and risk among all individuals at each site. Fi-
nally, the small prevalence of P. falciparum infection
among HIV-positive women who were receiving co-
trimoxazole during pregnancy [20] may have reduced
the power to detect variations in resistance and toler-
ance to malaria.
Conclusions
This study shows that pregnant women may reduce the
deleterious impact of P. falciparum infection through
two conceptually different types of defence against mal-
aria, namely, one that targets the parasite (resistance),
and the other that prevents the damage induced by the
infection (tolerance) [7, 8]. Down-regulation of malaria-
induced inflammation may mediate this tolerance
phenotype, although other mechanisms that increase the
resilience to tissue injuries, such as metabolic adaptation
to tissue repair and detoxification of pathogen by-
products [11, 47], might still be involved. Making the
distinction between resistance mechanisms that restrict
parasite multiplication from those that minimise the
harm caused by the infection [7, 8] is important to
understand how reductions in transmission intensity can
affect host defences and, therefore, the clinical presenta-
tion of P. falciparum infections, as well as for the design
of new host-directed therapies [9, 48, 49].
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